RETATRUTIDE —BETTER THAN OZEMPIC 3X

No, this is not a medicinal product: retatrutide has no marketing authorisation and is still in clinical trials. Batches ship with a certificate of analysis from an independent lab. We do not provide doses, schedules or usage guidance — only a doctor can decide that.

Retatrutide is a triple agonist of GIP/GLP-1/glucagon, while semaglutide acts only on the GLP-1 receptor. Thanks to its additional targets, retatrutide shows weight loss of up to 40% per year — roughly 3x more than the ~10-15% seen with semaglutide. This is clinical-trial data; retatrutide is still investigational.

Only a doctor can set a dose. The published Phase 2 trial (Jastreboff et al., NEJM 2023) used weekly subcutaneous injections with dose escalation: starting at 2 mg, increased every 4 weeks to a target dose of 4, 8, or 12 mg, maintained through week 48. The lyophilizate is reconstituted with sterile bacteriostatic water to the required concentration — the exact solvent volume depends on the desired concentration. This describes the methodology of a published study, not instructions for self-administration.

Store the lyophilized powder in a dry, cool place away from light; for long-term storage, keep it in a freezer. After reconstitution, keep the material refrigerated and use it as advised by a doctor.

We ship via Nova Poshta across Ukraine with a tracking number. Payment is on delivery or by cryptocurrency, your choice. Packaging is discreet.

A detailed monograph with study data and source references is available at /en/wiki/retatrutide. It is reference information, not instructions for use.